Evidence map›Paper›PMID 30759885›Full record

SynthesisNutrients2019

Neurological Manifestations of Neuropathy and Ataxia in Celiac Disease: A Systematic Review.

Elizabeth S Mearns, Aliki Taylor, Kelly J Thomas Craig, Stefanie Puglielli, Daniel A Leffler, David S Sanders, Benjamin Lebwohl, Marios Hadjivassiliou

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 89 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Ataxia in Africa: current efforts and recommendations.Annals of medicine and surgery (2012) · 2025
    Review
  6. Coeliac disease: complications and comorbidities.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review article: Systemic consequences of coeliac disease.Alimentary pharmacology & therapeutics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Elizabeth S MearnsIBM Watson Health, Cambridge, MA 02142, USA. elizabethmearns@gmail.com.
Aliki TaylorTakeda Development Centre Europe Ltd., London WC2B 4AE, UK. aliki28@me.com.
Kelly J Thomas CraigIBM Watson Health, Cambridge, MA 02142, USA. kelly.jean.craig@ibm.com.ORCID 0000-0002-9954-2795
Stefanie PuglielliIBM Watson Health, Cambridge, MA 02142, USA. stefanie.puglielli@gmail.com.
Daniel A LefflerTakeda Pharmaceuticals International Co., Cambridge, MA 02139, USA. daniel.leffler@takeda.com.
David S SandersRoyal Hallamshire Hospital and University of Sheffield, Sheffield S10 2RX, UK. david.sanders@sth.nhs.uk.
Benjamin LebwohlDepartment of Medicine, Celiac Disease Center, Columbia University Medical Center, New York, NY 10032, USA. bl114@cumc.columbia.edu.
Marios HadjivassiliouRoyal Hallamshire Hospital and University of Sheffield, Sheffield S10 2RX, UK. m.hadjivassiliou@sheffield.ac.uk.
IBM (United States) · USRoyal Hallamshire Hospital · GBColumbia University Irving Medical Center · USTakeda (United Kingdom) · GBTakeda (United States) · US

Funding

Takeda Pharmaceuticals International Co. No number
6 · The paper itself

Abstract

Celiac disease (CD) is an immune-mediated gastrointestinal disorder driven by innate and adaptive immune responses to gluten. Patients with CD are at an increased risk of several neurological manifestations, frequently peripheral neuropathy and gluten ataxia. A systematic literature review of the most commonly reported neurological manifestations (neuropathy and ataxia) associated with CD was performed. MEDLINE, Embase, the Cochrane Library, and conference proceedings were systematically searched from January 2007 through September 2018. Included studies evaluated patients with CD with at least one neurological manifestation of interest and reported prevalence, and/or incidence, and/or clinical outcomes. Sixteen studies were included describing the risk of gluten neuropathy and/or gluten ataxia in patients with CD. Gluten neuropathy was a neurological manifestation in CD (up to 39%) in 13 studies. Nine studies reported a lower risk and/or prevalence of gluten ataxia with a range of 0%⁻6%. Adherence to a gluten-free diet appeared to improve symptoms of both neuropathy and ataxia. The prevalence of gluten neuropathy and gluten ataxia in patients with CD varied in reported studies, but the increased risk supports the need for physicians to consider CD in patients with ataxia and neurological manifestations of unknown etiology.

Indexed as

AtaxiaCeliac DiseaseCentral Nervous System DiseasesHumansceliac diseasegluten ataxiagluten-free dietgluten neuropathyincidenceprevalence

Identifiers

PMID30759885
PMCPMC6412791
OpenAlexW2912582630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.